Cellectar Biosciences, Inc(NASDAQ:CLRB) 
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refr...
Website: http://www.cellectar.com
Founded: 1996
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 8.71
H 8.71
L 6.91
C 7.81
V 1,648,520
10EMA 7.81
20EMA 7.81
60EMA 7.81
120EMA 7.81
250EMA 7.81